Abstract: An object of the present invention is to provide an effective method of predicting an effect of treatment by a PD-1/PD-L1 blockade, which is a method of predicting whether or not PD-1/PD-L1 blockade is effective for treatment of a subject suffering from a malignant tumor, which comprises detecting abnormality of genome relating to effectiveness of the PD-1/PD-L1 blockade in a tumor cell taken from the subject and evaluating the PD-1/PD-L1 blockade as useful for the treatment of the subject when there is the abnormality.

Abstract: A method for detecting T-cell lymphoma characterized in that gene mutations of at least one base selected from a group comprising base numbers 50, 331, 334, and 482 or gene mutations of base numbers 49 to 51 in the base sequence of an RHOA gene collected from a subject are analyzed, and the analysis results and T-cell lymphoma are associated with each other.

Abstract: An object of the present invention is to provide an effective method of predicting an effect of treatment by a PD-1/PD-L1 blockade, which is a method of predicting whether or not PD-1/PD-L1 blockade is effective for treatment of a subject suffering from a malignant tumor, which comprises detecting abnormality of genome relating to effectiveness of the PD-1/PD-L1 blockade in a tumor cell taken from the subject and evaluating the PD-1/PD-L1 blockade as useful for the treatment of the subject when there is the abnormality.

Abstract: The present invention provides polypeptide and antibody for assessing predisposition of myelodysplastic syndrome or myeloid tumor, and method for screening therapeutic drugs therefor. The polypeptide comprises at least a portion of the U2AF35 gene, at least a portion of the ZRSR2 gene, at least a portion of the SFRS2 gene, or at least a portion of the SF3B1 gene, and is able to serve as a marker for evaluating predisposition for myelodysplastic syndromes or a myelogenous tumor.

Abstract: A method for detecting T-cell lymphoma characterized in that gene mutations of at least one base selected from a group comprising base numbers 50, 331, 334, and 482 or gene mutations of base numbers 49 to 51 in the base sequence of an RHOA gene collected from a subject are analyzed, and the analysis results and T-cell lymphoma are associated with each other.

Abstract: [Problem] To provide a method for assessing myelodysplastic syndrome or myeloid tumor predisposition, on the basis of a genetic diagnosis using massively parallel sequencing technology, as well as a peptide and antibody therefor, and a method for screening for candidate therapeutic drugs or prophylactic drugs for myelodysplastic syndrome or myeloid tumor. [Solution] A method for assessing whether or not there is a predisposition for the occurrence of myelodysplastic syndrome or myeloid tumor, wherein the method comprises a step for using a sample that includes a subject's human genes and detecting a mutation in at least one gene from among the U2AF35 gene, the ZRSR2 gene, the SFRS2 gene, or the SF3B1 gene.

Abstract: In a driving mechanism for a vacuum circuit breaker including a movable contact, a stationary contact and bellows permitting reciprocating movement of the movable contact, a bell crank is oscillated by an actuating device to reciprocate a drive bar connected to the movable contact. As the movable and the stationary contacts are worn, the displacement of the drive is increased. The increase is detected and the pivot point of the bell crank is shifted toward the stationary contact. Thus retracted position of the movable contact is shifted in accordance with the wear, and the stroke of the movable contact and hence the amplitude of variation in length of the bellows are maintained constant in spite of the wear.